Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

What is the future of targeted therapy in rheumatology: biologics or small molecules?

Mócsai A, Kovács L, Gergely P.

BMC Med. 2014 Mar 13;12:43. doi: 10.1186/1741-7015-12-43. Review.

2.

[Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].

Frommer KW, Geyer M, Firestein GS.

Z Rheumatol. 2012 Aug;71(6):460-7. doi: 10.1007/s00393-011-0877-4. German.

PMID:
22875571
4.

[New kinase inhibitors].

Rubbert-Roth A.

Z Rheumatol. 2012 Aug;71(6):479-84. doi: 10.1007/s00393-011-0880-9. German.

PMID:
22777068
5.

Back to the future: oral targeted therapy for RA and other autoimmune diseases.

O'Shea JJ, Laurence A, McInnes IB.

Nat Rev Rheumatol. 2013 Mar;9(3):173-82. doi: 10.1038/nrrheum.2013.7. Epub 2013 Feb 19. Review.

6.

[Rheumatology].

Scherer HU, Burmester GR.

Internist (Berl). 2005 Aug;46(8):882-91. Review. German.

PMID:
15997385
7.

[A short history of anti-rheumatic therapy--VII. Biological agents].

Pasero G, Marson P, Gatto B.

Reumatismo. 2011 Nov 9;63(3):185-94. doi: 10.4081/reumatismo.2011.185. Italian.

PMID:
22257920
8.

[Role of orthopedic rheumatologist in the therapy of rheumatic diseases with biologics].

Rehart S, Henniger M.

Orthopade. 2014 Jun;43(6):585-93; quiz 594-5. doi: 10.1007/s00132-014-2321-3. German.

PMID:
24891252
9.

[Modern disease-modifying antirheumatic drugs].

Müller-Ladner U, Richter K, Tarner IH.

Internist (Berl). 2015 Mar;56(3):307-14. doi: 10.1007/s00108-014-3651-2. German.

PMID:
25700648
10.

A glimpse into the future: recombinant proteins and small molecules for targeted therapies in rheumatic diseases.

Kalden JR, Braun J.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S168-70.

PMID:
19822067
11.

[New biologics and orally available compounds. What is still in the pipeline?].

Grünke M, Bastian H, Schulze-Koops H, Burmester GR.

Z Rheumatol. 2010 Sep;69(7):626-32. doi: 10.1007/s00393-009-0531-6. Review. German.

PMID:
20725732
12.

Milestones in anti-inflammatory therapy.

Huskisson EC.

Eur J Rheumatol Inflamm. 1987;8(1):3-5.

PMID:
3497809
13.

Pharmacogenetics: implications for therapy in rheumatic diseases.

Davila L, Ranganathan P.

Nat Rev Rheumatol. 2011 Aug 9;7(9):537-50. doi: 10.1038/nrrheum.2011.117. Review. Erratum in: Nat Rev Rheumatol. 2015 May;11(5):258.

PMID:
21826093
14.

Advances in rheumatology: new targeted therapeutics.

Tak PP, Kalden JR.

Arthritis Res Ther. 2011 May 25;13 Suppl 1:S5. doi: 10.1186/1478-6354-13-S1-S5. Review.

15.

[Recent progress in clinical trials for rheumatic diseases].

Tanaka Y.

Nihon Rinsho. 2009 Mar;67(3):619-25. Review. Japanese.

PMID:
19280942
16.

[Personalized medicine in cytokine-targeted therapy].

Behrens F, Köhm M.

Z Rheumatol. 2013 Feb;72(1):41-8. doi: 10.1007/s00393-011-0886-3. German.

PMID:
23392600
17.

Rheumatology--past, present, and future.

Schattenkirchner M.

Eur J Rheumatol Inflamm. 1987;8(1):31-7.

PMID:
3497810
18.

Garden of therapeutic delights: new targets in rheumatic diseases.

Waldburger JM, Firestein GS.

Arthritis Res Ther. 2009;11(1):206. doi: 10.1186/ar2556. Epub 2009 Jan 30. Review.

19.

[Drug delivery system of anti-inflammatory and anti-rheumatic drugs].

Kawai S.

Nihon Rinsho. 1998 Mar;56(3):782-7. Review. Japanese.

PMID:
9549373
20.

Tumor necrosis factor as a therapeutic target of rheumatologic disease.

Ackermann C, Kavanaugh A.

Expert Opin Ther Targets. 2007 Nov;11(11):1369-84. Review.

PMID:
18028004
Items per page

Supplemental Content

Write to the Help Desk